AI GxP validation for regulated life sciences
Business Case

Taking an AI Plan to Your Board: What to Put In It

Boards fund plans they can judge. What to include (scope, sequencing, the regulatory position, what you will stop doing) and the three questions a sceptical non-executive will ask that most plans cannot answer.

Cybroscape Technologies5 min read

Key takeaway

Boards fund plans they can judge. What to include (scope, sequencing, the regulatory position, what you will stop doing) and the three questions a sceptical non-executive will ask that most plans cannot answer.

Boards do not fund technologies. They fund plans they can judge, from people who seem to understand the risks. An AI plan that reads like a vendor summary gets polite questions and no budget.

What follows is the shape that tends to work in a regulated business, and the questions a sceptical non-executive will ask.

What belongs in the plan

  • The problem, in operational terms. Not "adopt AI". "Validation is the critical path on four of our six system projects this year, and we are hiring contractors at a premium to absorb it."
  • Scope, narrow and specific. Two or three use cases, named, with the systems and teams involved. A plan covering everything will be read as a plan covering nothing.
  • Sequencing with a decision point. Pilot, evaluate against criteria set in advance, then decide. Boards respond well to a stated stopping condition, because it shows you have considered failure.
  • The regulatory position, stated plainly. What stays a human decision, how you would answer an inspector, which standards apply. In this industry that paragraph does more for credibility than any projection.
  • Honest cost, five years. Including validation, review time and revalidation — see what AI actually costs.
  • What you will stop doing. The most persuasive line in any plan, and the most often missing.

The three questions you will be asked

"What happens if it gets something wrong?" The right answer is specific: here is the error type we expect, here is who catches it, here is what it costs when they do, and here is the one failure mode that would be serious and how the design prevents it reaching a record.

"What does this do to our regulatory risk?" Answer honestly in both directions. It adds a system to validate and maintain. It can reduce risk where it makes evidence more consistent and traceability continuous. Claiming only upside is how you lose the room.

"Why now, and why us?" If the honest answer is that competitors are doing it, say so and give the operational reason as well. Boards in this sector have seen enough technology cycles to recognise fashion, and they trust the person who distinguishes it from need.

What weakens a plan

  • Vendor numbers presented as your numbers. A "70% reduction" from a case study is a vendor's claim about someone else's process. Use your own baseline or none.
  • No baseline at all. If you cannot say what the current process costs and how often it goes wrong, you cannot show improvement later. Measure first — see validation metrics that matter.
  • Headcount reduction as the benefit. In a quality function this reads as reducing oversight, which is the opposite of what you want a board to approve.
  • A plan with no end state. Pilots that fund more pilots.

If you want the strongest single slide: the current cost and error rate of the process, the pilot result against pre-set criteria, and the decision you are asking for. Everything else is supporting material.

Structure for the pilot itself is in running a 90-day GxP AI pilot, and the strategy work in AI strategy.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Your shortlist criteria
Fits how you validate (CSV or CSA)Must
Part 11 and Annex 11 records and signaturesMust
Evidence you can export and keepMust
AI features you can actually validateShould
Total cost over three years, validation includedShould
Supplier evidence you can rely onNice
Weights set before demosSo the demo cannot set them for you
A fair comparison weighs the same criteria for every option, and sets the weights before the first demo. Every platform suits some teams; the shortlist is about which one suits yours.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
ai strategy board pharmaai roadmap life sciencespresent ai plan executivesai investment case regulated
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

What should an AI plan for the board contain?

The problem in operational terms rather than 'adopt AI'; a narrow scope of two or three named use cases; sequencing with a decision point and a stated stopping condition; the regulatory position including what stays a human decision; honest five-year cost including validation and review time; and what you will stop doing.

What will a sceptical non-executive ask?

What happens if it gets something wrong — answer with the specific error type, who catches it, what it costs, and the one serious failure mode and how the design prevents it reaching a record. What it does to regulatory risk — answer in both directions. And why now and why us — distinguish need from fashion honestly.

What weakens an AI plan?

Vendor case-study numbers presented as your own; no baseline, so improvement cannot be shown later; headcount reduction framed as the benefit, which in a quality function reads as reducing oversight; and a plan with no end state, where pilots fund more pilots.

What is the strongest single slide?

The current cost and error rate of the process, the pilot result measured against criteria set in advance, and the specific decision you are asking the board to make. Everything else is supporting material.

Should the plan admit uncertainty?

Yes. A stated range with assumptions, and an explicit stopping condition if the pilot misses its criteria, both increase credibility. Boards in this sector have seen enough technology cycles to trust the person who distinguishes need from fashion.

Keep reading

All articles
Business CaseWhat AI Actually Costs in a Regulated CompanyThe licence is the visible number and rarely the biggest one. Validation, monitoring, SOP changes, training, revalidation on every model update and the review time that never goes away, all priced honestly. · 5 min readBusiness CaseGxP AI Software ROI: A Working Economic Model for Your QA Head and CFOThe real numbers behind GxP AI software adoption: validation cycle time, scripted-test effort delta, re-baseline cost, and the model your CFO will accept. · 4 min readThought LeadershipIn clinical writing, speed is not the bottleneck. Review is.Drafting is a small part of clinical document cycle time; review is the bottleneck. Source traceability, cross-document consistency checks and clear limits on AI-drafted judgement shorten the cycle more than faster drafting. · 3 min readCloudCloud & SaaS validation: the shared-responsibility matrix regulators expectHow to leverage provider evidence, validate tenant configuration, and stay defensible. · 6 min readEquipment QualificationCommissioning is the biggest reduction available in a qualification packageEquipment arrives already tested at FAT, SAT and commissioning. Annex 15 lets you use that. The three conditions that have to hold, and why they cannot be retrofitted. · 7 min readChecklistThe Complete GxP Validation Checklist: from URS to VSRA single-page checklist of every artefact, every review gate and every regulator-facing evidence element in a modern V-model validation. · 3 min readMed DeviceCSA and QMSR for medical device manufacturers: what changedFDA’s final CSA guidance covers production and quality system software, not device software. It scales testing and records to process risk, and fits with ISO 13485 under QMSR, effective February 2026. · 3 min readClinicalCSR authoring with AI: how to keep every claim source-traceableHow TraceDraft turns AE listings and SAS data into an ICH E3 CSR where every claim traces to source. · 6 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.